Pharmasset Inc.

According to Citi, Pharmasset (NASDAQ: VRUS) 12-month target price of $200 is based on DCF analysis using a 10% discount rate that runs through 2025 with no terminal growth rate. Citi said that it believes that a 10% discount rate reflects a normalized rate that is appropriate given historical...

J.P. Morgan has raised its price target on Pharmasset (NASDAQ: VRUS) from $100 to $200 in light of “Biotech Week”Day 2 and portfolio analysis of the stock. According to J.P. Morgan, “[The change in price target] is based on consistent positive feedback from the Hep C arena and building momentum...